Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL).

8078 Background: Optimal therapy for RIL remains controversial, although treatment options often include rituximab (R). Based on phase I-II studies of FND (fludarabine 25 mg/m2, d1-3; mitoxantrone ...